Carvedilol Tablet, Film Coated
Product Images NDC 55154-2649

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 55154-2649). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25mg Bag Label (Bd0f2596 A192 4b0e 836f 4a09816408a4 00)

Carvedilol Tablets USP 25 mg, film-coated oral tablets, package contains 10 tablets. Label includes dosage unit strength, storage instructions at 20°C to 25°C, warnings for child safety and moisture protection, and dispensing information. Distributed by Cardinal Health 107, LLC and associated with Major Pharmaceuticals and Glenmark Pharmaceuticals.*

FDA Label Image

3.125mg Bag Label (Bd0f2596 A192 4b0e 836f 4a09816408a4 01)

Carvedilol Tablets, USP 3.125 mg label for a film-coated tablet. The package contains 10 tablets. It includes storage instructions, dosage note, and warnings about use. The drug is distributed by Cardinal Health, Dublin, OH, with packaging details from Major Pharmaceuticals, Indianapolis, IN. The label includes NDC 55154-2641-0 and mentions institutional use and safety closures.*

FDA Label Image

Figure-1 (Figure 1)

A line graph comparing % mortality over a 21-month period between Carvedilol and placebo groups. The x-axis represents months and the y-axis shows % mortality. The placebo group exhibits higher mortality rates than the Carvedilol group. A p-value of 0.0014 is indicated on the graph.*

FDA Label Image

Figure-2 (Figure 2)

A hazard ratio forest plot showing multiple patient subgroups including men, women, age groups, race, diabetic status, ischemic condition, heart rate levels, systolic blood pressure levels, and spironolactone use. Each subgroup has a dot representing the hazard ratio with horizontal lines indicating confidence intervals, plotted along an axis ranging from 0.0 to 2.0. The plot includes a reference line at hazard ratio 1.0 for comparison.*

FDA Label Image

Figure-3 (Figure 3)

A survival analysis line graph titled 'Survival Analysis for CAPRICORN (intent-to-treat)' showing percent mortality over 24 months. Two lines represent 'Placebo' and 'Carvedilol' groups, with mortality increasing over time. The graph includes a P-value of 0.03 indicating statistical significance between groups.*

FDA Label Image

Figure-4 (Figure 4)

A forest plot chart titled 'Figure 4. Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios for mortality across various patient subgroups. The subgroups include age, gender, timing of randomization post-MI, prior IV/oral beta-blocker use, Killip class, thrombolytic use, PTCA for MI, CHF status, diuretic use during MI, angina presence, hypertension, diabetes, heart rate, and systolic blood pressure. Each subgroup is represented by a dot and confidence interval lines on a horizontal hazard ratio scale from 0.4 to 1.3.*

FDA Label Image

Logo (Logo)

FDA Label Image

Logo1 (Logo1)

FDA Label Image

Carvedilol-chemical-structure (Structure)

Chemical structure of carvedilol showing its molecular framework, including aromatic rings and functional groups characteristic of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.